

MIGRAINE

WHAT IS MIGRAINE?¹



- A common and disabling neurological condition
- Attacks of headache and other symptoms because of an abnormally sensitive brain

HOW COMMON IS MIGRAINE?³⁻⁶

1 billion worldwide



1 in 4 homes



1 in 5 women



1 in 16 men



1 in 11 children



IS MIGRAINE INHERITED?^{6,7}


If 1 parent has migraine:
50% chance of a child having it too




If both parents have migraine:
75% chance of a child having it too



WHAT ARE MIGRAINE SYMPTOMS?^{1,2}



WHAT IS AURA?¹



- One-third of people with migraine
- Reversible attacks of neurological symptoms
- Usually last from a few minutes up to an hour


CAN MIGRAINE GET WORSE OVER TIME?¹³⁻¹⁹



- 2-3% of people with episodic migraine every year develop chronic migraine
- Chronic migraine indicates headache happening on half of all days for 3 or more months
- Risk factors for chronic migraine

Stressful life events
Head injury
Excessive caffeine use
Overuse of opioids and barbiturates
Not having an optimized acute treatment plan
More headache days per month
Persistent frequent nausea with migraine
Snoring and sleep apnea
Other pain conditions
Depression
Anxiety
Allodynia (skin and scalp sensitivity to touch)
Allergic rhinitis

HOW IS MIGRAINE TREATED?⁸⁻¹²



Follow us on Facebook:

<https://www.facebook.com/pages/American-Headache-Society/67380083618>

<https://www.facebook.com/americanmigrainefoundation>

<https://www.facebook.com/AHMAorg>

Follow us on Twitter:

@ahsheadache

@amfmigraine

@ahmaorg

@headachejournal

www.AmericanHeadacheSociety.org - American Headache Society (AHS) • www.AmericanMigraineFoundation.org - American Migraine Foundation (AMF)

<http://ahma.memberclicks.net/> - American Headache and Migraine Association (AHMA) • www.headachejournal.org - Headache: The Journal of Head and Face Pain

References
1. Headache Classification Subcommittee of the International Headache Society. International Classification of Headache Disorders, 3rd edition beta. Cephalalgia. 2013;33:629-808.
2. Charles A. "Head Talks: Pathophysiology." Scottsdale Headache Symposium, November 21, 2014.
3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-9.
4. Robbins MS, Lipton RB. The epidemiology of primary headache disorders. Semin Neurol. 2010;30:107-19.
5. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96.
6. Wöber-Bingöl C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17:341.
7. Stewart WF, Staffa J, Lipton RB, Ottman R. Familial risk of migraine: a population-based study. Ann Neurol. 1997;41:166-72.
8. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-45.
9. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346-53.

10. Mamura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3-20.
11. Buse DC. Multidisciplinary migraine management. Pain Med News. 2014;12:14-25.
12. Campbell JK, Penzien DB, Wall EM, US Headache Consortium. Evidence-based guidelines for migraine headache: behavioral and physical treatments. Accessed at <http://tools.aan.com/professionals/practice/pdfs/g0089.pdf>
13. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157-68.
14. Lipton RB, Serrano D, Buse DC. Migraine: Epidemiology, Progression, Prognosis and Comorbidity. In: Robbins MS, Grosberg BM, and Lipton RB (Eds.) Neurology In Practice: Headache, 1st ed. London: Wiley-Blackwell; 2013: 64-87.
15. Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688-95.
16. Reed ML, Fanning KM, Serrano D, Buse DC, Lipton RB. Persistent frequent nausea is associated with progression to chronic migraine. AMPP Study Results. Headache. 2015;55:76-87.
17. Ashino S, Serrano D, Lipton RB, Majeed M, Manack AN, Tulek CC, Reed ML, Buse DC. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13:615-624.
18. Ashino S, Buse DC, Majeed M, Manack A, Serrano D, Tulek CC, Lipton RB. Self-reported anxiety as a risk factor for migraine chronicity: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2010;50(Suppl. 1):4.
19. Martin VT, Fanning KM, Serrano D, Buse DC, Reed ML, Bernstein JA, Lipton RB. Chronic rhinitis and its association with headache frequency and disability in persons with migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Cephalalgia. 2014;34:336-48.